Biosafety assays for the diagnosis and prediction of drug-related complement pathology

Informazioni relative al progetto

Biosafety

ID dell’accordo di sovvenzione: 952520

DOI

10.3030/952520

Progetto chiuso

Data della firma CE 6 Luglio 2020

Data di avvio 1 Settembre 2020

Data di completamento 31 Agosto 2023

Finanziato da

• Twinning of research institutions

Costo totale

€ 900 000,00

Contributo UE

€ 900 000,00

Coordinato da

SEMMELWEIS EGYETEM
Hungary

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (8)

“BIOSAFETY” Joint Summer School (A and B)

A joint summer school will be organised in Budapest

Report about the meetings with interest groups from industry

Meetings with interest groups from industry will be reported

KPIs definition for “BIOSAFETY”

This list of putative KPIs will be thoroughly discussed with the expert partnering institutions and a final list will be compiled

Impact assessment by the end of the project and forecast of the following 3-year period

Impact assessment will be performed in a 3year window by the end of the project

"„The industrial day"" and ""Knowledge Transfer Zone"" through meetings between research institutions and enterprises"

Experts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstormingExperts from the partnering institutions will be invited to provide inspirational lectures and topic related events to stimulate brainstorming

Impact assessment in the 3-year period prior to “BIOSAFETY” for all KPIs

Impact assessment will be performed in a 3year window at the begining of the project

Publication history of Semmelw in the last 3 years
“BIOSAFETY” Thematic Workshop (A and B)

Thematic workshop for example biosafety markers un indispensable tool to predict unwanted side effects relevant to BIOSAFETY project will be organised

Open Research Data Pilot (2)

First data Management Plan
Final Data Management Plan

Websites, patent fillings, videos etc. (1)

Development of the project logo/brand and brochure/flyer

Developing a project logo and setting up a project website are two critical steps which will pave the way for an effective Public Relations PR strategy for BIOSAFETYA brochure and flyer will also be developed in the first year of the project to support the dissemination of BIOSAFETY in different events They will be revised when needed

Pubblicazioni

Peer reviewed articles (15)

Effect of the Addition of Alginate and/or Tetracycline on Brushite Cement Properties

Autori: Claudia Morilla, Elianis Perdomo, Ana Karla Hernández, Ramcy Regalado, Amisel Almirall, Gastón Fuentes, Yaima Campos Mora, Timo Schomann, Alan Chan, Luis J. Cruz
Pubblicato in: Molecules, Numero 26/11, 2021, Pagina/e 3272, ISSN 1420-3049
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/molecules26113272

Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy

Autori: Yang Hao,Chih Kit Chung,Zhenfeng Yu,Ruben V. Huis in ‘t Veld,Ferry A. Ossendorp,Peter ten Dijke,and Luis J. Cruz.
Pubblicato in: Pharmaceutics, 2022, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14010120

A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor

Autori: Dezsi L, Meszaros T, Kozma GT, H-Velkei M, Olah CZ, Szabo M, Patko Zs, Fulop T, Hennies M, Szebeni M, Barta BA, Merkely B, Radovits T, and Szebeni J
Pubblicato in: GeroScience, Numero 44(2), 2022, Pagina/e 597–618, ISSN 2509-2723
Editore: Springer
DOI: 10.1007/s11357-021-00495-y

Zinc-Phthalocyanine-Loaded Extracellular Vesicles Increase Efficacy and Selectivity of Photodynamic Therapy in Co-Culture and Preclinical Models of Colon Cancer

Autori: Pablo Lara, Ruben V. Huis in ‘t Veld, Carla Jorquera-Cordero, Alan B. Chan, Ferry Ossendorp, Luis J. Cruz
Pubblicato in: Pharmaceutics, Numero 13/10, 2021, Pagina/e 1547, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13101547

The Incorporation of Etanercept into a Porous Tri-Layer Scaffold for Restoring and Repairing Cartilage Tissue

Autori: Campos, Yaima; Fuentes, Gastón; Almirall, Amisel; Que, Ivo; Schomann, Timo; Chung, Chih Kit; Jorquera Cordero, Carla; Quintanilla Sierra, Luis; Rodríguez Cabello, José Carlos; Chan, Alan; Cruz, Luis
Pubblicato in: Pharmaceutics, Numero 1, 2022, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14020282

Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines

Autori: Szebeni J, Storm G, Ljubimova JY, Castells M, Phillips EJ, Turjeman K, Barenholz Y, Crommelin DJA and Dobrovolskaia MA
Pubblicato in: Nature Nanotechnology, Numero 17(4), 2022, Pagina/e 337-346, ISSN 1748-3387
Editore: Nature Publishing Group
DOI: 10.1038/s41565-022-01071-x

Eculizumab suppresses zymosan-induced release of inflammatory cytokinesIL-1α, IL-1β, IFN-γ and IL-2 in autologous serum-substituted PBMC cultures:Relevance to cytokine storm in Covid-19

Autori: Bakos T. Kozma GT, Szebeni J, Szénási G.
Pubblicato in: Biomedicine & Pharmacotherapy, Numero 166, 2023, Pagina/e 115294, ISSN 0753-3322
Editore: Elsevier Masson
DOI: 10.1016/j.biopha.2023.115294

Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19

Autori: Kokeny G, Bakos T, Barta BA, Nagy GV, Meszaros T, Kozma GT, Szabo A, Szebeni J, Merkely B, Radovits T
Pubblicato in: International Journal of Molecular Sciences, Numero 24, 2023, Pagina/e 18, ISSN 1661-6596
Editore: MDPI
DOI: 10.3390/ijms24021138

Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion

Autori: Gergely Milosevits,Tamás Mészáros, Erik Őrfi PharmD, Tamás Bakos, Miklós Garami, Gábor Kovács, László Dézsi, Péter Hamar, Balázs Győrffy, András Szabó, Gábor Szénási,János Szebeni.
Pubblicato in: Nanomedicine: Nanotechnology, Biology and Medicine, 2021, ISSN 1549-9634
Editore: Elsevier BV
DOI: 10.1016/j.nano.2021.102366

Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm

Autori: Gergely Tibor Kozma, Tamás Mészáros, Tamás Bakos, Mark Hennies, Dániel Bencze, Barbara Uzonyi, Balázs Győrffy, Edward Cedrone, Marina A. Dobrovolskaia, Mihály Józsi and János Szebeni.
Pubblicato in: Front. Immunol, Numero 12, 2021, ISSN 1664-3224
Editore: Front. Immunol
DOI: 10.3389/fimmu.2021.642860

To “PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives

Autori: Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, Dobrovolskaia MA
Pubblicato in: Advanced Drug Delivery Reviews, Numero 180, 2022, Pagina/e 22, ISSN 0169-409X
Editore: Elsevier BV
DOI: 10.1016/j.addr.2021.114079

The Hypertensive Effect of Amphotericin B-Containing Liposomes (Abelcet) in Mice: Dissecting the Roles of C3a and C5a Anaphylatoxins, Macrophages and Thromboxane

Autori: Orfi E, Hricisak L, Dezsi L, Hamar P, Benyo Z, Szebeni J, Szenasi G
Pubblicato in: Biomedicines, Numero 10(7), 2022, Pagina/e 1764, ISSN 2227-9059
Editore: MDPI AG
DOI: 10.3390/biomedicines10071764

Role of anti-polyethylene glycol (PEG) antibodies in the allergic reactions to PEG-containing Covid-19 vaccines: Evidence for immunogenicity of PEG

Autori: Kozma TG, Meszaros T, Berenyi P, Facsko R, Patko Zs, Oláh Cs, Nagy J, Fulop T, Glatter K, Radovits T, Merkely B, Szebeni J.
Pubblicato in: Vaccine, Numero 41, 2023, Pagina/e 4561-4570, ISSN 0264-410X
Editore: Elsevier BV
DOI: 10.1016/j.vaccine.2023.06.009

Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Autori: Ana Luiza C. de S. L. Oliveira, Timo Schomann, Lioe-Fee de Geus-Oei, Ellen Kapiteijn, Luis J. Cruz, Raimundo Fernandes de Araújo Junior
Pubblicato in: Pharmaceutics, Numero 13/8, 2021, Pagina/e 1321, ISSN 1999-4923
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics13081321

Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA–Lipid Complexes

Autori: Szebeni, J;Kiss, B;Bozo, T;Turjeman, K;Levi-Kalisman, Y;Barenholz, Y;Kellermayer, M
Pubblicato in: ACS NANO, Numero 17, 2023, Pagina/e 13147-13157, ISSN 1936-0851
Editore: American Chemical Society
DOI: 10.1021/acsnano.2c11904